← Leaderboards
James E Bradner
Dana-Farber Cancer Inst
$6,722,003
Attributed
$7,893,945
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2008–18$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$7,893,945 · 7
By mechanism
P01$3,001,268 · 2
R01$1,757,913 · 1
P50$1,232,558 · 1
K08$789,127 · 1
U01$710,703 · 1
R21$402,376 · 1
Top collaborators
- Saptarsi Haldar3 shared
- Timothy Mckinsey3 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Jun Qi$6,834,111
- Kenneth C Anderson$25,995,373
- Teru Hideshima$1,761,647
- Ramesh A Shivdasani$32,986,881
- Michael L. Cheng$463,885
Others in their field
Top investigators on “Inhibitor/Antagonist”
- John M Lachin · George Washington University$117,867,649
- David M Nathan · Massachusetts Institute Of Technology$117,867,649
- Randall J Bateman · Washington University$110,978,751
- David Heimbrook · Leidos Biomedical Research, Inc.$72,139,282
- Keri Hammel · The Emmes Company, Llc$53,700,408
- Walter John Curran · Thomas Jefferson University$32,790,605
Research focus
Inhibitor/AntagonistProteinsProgramsBiologicalCellsEpigenetic ProcessIn VivoPathway InteractionsLaboratoriesStructureTherapeutic TargetBromodomainTranslationsIn VitroBiologyComplexGenesSmall MoleculeBaseMalignant NeoplasmsChromatinLeadPropertyGene Expression
Grant awards (28)
Novel Epigenetic Approaches in AML$471,094
P01 · FY2018 · CA · contact PI
Core E: Experimental Therapeutics Core$158,120
P01 · FY2018 · CA · contact PI
Novel Epigenetic Approaches in AML$471,092
P01 · FY2017 · CA · contact PI
Targeting the Multiple Myeloma Epigenome$259,246
P50 · FY2017 · CA · contact PI
Core E: Experimental Therapeutics Core$158,120
P01 · FY2017 · CA · contact PI
Regulation of Chromatin Signaling in Heart Failure by BET Bromodomain Proteins$881,694
R01 · FY2016 · HL
Novel Epigenetic Approaches in AML$471,092
P01 · FY2016 · CA · contact PI
Targeting the Multiple Myeloma Epigenome$243,518
P50 · FY2016 · CA · contact PI
Core E: Experimental Therapeutics Core$158,120
P01 · FY2016 · CA · contact PI
Regulation of Chromatin Signaling in Heart Failure by BET Bromodomain Proteins$827,495
R01 · FY2015 · HL
Novel Epigenetic Approaches in AML$471,079
P01 · FY2015 · CA · contact PI
Targeting the Multiple Myeloma Epigenome$246,108
P50 · FY2015 · CA · contact PI
Screening for inhibitors of the CBX chromodomain$190,313
R21 · FY2015 · CA · contact PI
Core E: Experimental Therapeutics Core$164,996
P01 · FY2015 · CA · contact PI
Regulation of Chromatin Signaling in Heart Failure by BET Bromodomain Proteins$48,724
R01 · FY2015 · HL
Novel Epigenetic Approaches in AML$477,555
P01 · FY2014 · CA · contact PI
Targeting the Multiple Myeloma Epigenome$243,569
P50 · FY2014 · CA · contact PI
Selective inhibition of BRDT for male contraception$236,496
U01 · FY2014 · HD · contact PI
Screening for inhibitors of the CBX chromodomain$212,063
R21 · FY2014 · CA · contact PI
Trageting the Multiple Myeloma Epigenome$240,117
P50 · FY2013 · CA · contact PI
Selective inhibition of BRDT for male contraception$230,899
U01 · FY2013 · HD · contact PI
Selective inhibition of BRDT for male contraception$243,308
U01 · FY2012 · HD · contact PI
Selective Inhibition of HDAC6 in Cancer Therapy$139,320
K08 · FY2012 · CA · contact PI
Selective Inhibition of HDAC6 in Cancer Therapy$139,320
K08 · FY2011 · CA · contact PI
Selective Inhibition of HDAC6 in Cancer Therapy$139,320
K08 · FY2010 · CA · contact PI
Selective Inhibition of HDAC6 in Cancer Therapy$139,320
K08 · FY2009 · CA · contact PI
Selective Inhibition of HDAC6 in Cancer Therapy$92,607
K08 · FY2009 · CA · contact PI
Selective Inhibition of HDAC6 in Cancer Therapy$139,240
K08 · FY2008 · CA · contact PI